Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P42330

UPID:
AK1C3_HUMAN

ALTERNATIVE NAMES:
17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5

ALTERNATIVE UPACC:
P42330; A8K2V0; B4DL37; Q5T2L1; Q96DJ1; Q96KI8; Q99530; Q9UCX1; Q9UII3; Q9UKL9

BACKGROUND:
The enzyme Aldo-keto reductase family 1 member C3, also referred to as Testosterone 17-beta-dehydrogenase 5, is integral to the regulation of steroid hormone levels. It functions by reducing prostaglandin D2, progesterone, and estrone, thereby modulating the bioavailability of testosterone, estradiol, and other critical hormones. Its ability to transform potent androgens into less active forms highlights its regulatory significance in steroid metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Aldo-keto reductase family 1 member C3 offers a promising avenue for developing novel treatments for hormonal imbalances and related diseases. Its key role in hormone regulation positions it as a valuable target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.